- Home
- NSAI vs TIL Comparison
NSAI vs TIL Comparison
Compare NSAI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSAI | TIL |
|---|---|---|
| Founded | 2026 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 52.2M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSAI | TIL |
|---|---|---|
| Price | $9.90 | $5.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.5K | ★ 31.5K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.82 | $5.62 |
| 52 Week High | $9.95 | $20.11 |
Technical Indicators
Market Signals| Indicator | NSAI | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 26.92 |
| Support Level | $9.82 | N/A |
| Resistance Level | $9.94 | $7.69 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 61.54 | 5.00 |
Price Performance
Historical ComparisonAbout NSAI NorthStrive Acquisition Corp I. Class A Ordinary Shares
NorthStrive Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.